# US 2022/0380285 A1 · Prenylated hydroxystilbenes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0380285 A1
- Document ID: US20220380285A1
- Status: Published application
- Kind: A1
- Application number: 17/825,827
- Filed: 2022-05-26
- Published: 2022-12-01
- Earliest claimed: 2011-05-04
- Assignees: Kynan Duke IP, LLC
- Applicants: Kynan Duke IP, LLC
- Inventors: Colin Charles Duke; Van Hoan TRAN; Rujee Kyokajee DUKE
- Web page: https://patentgrep.com/patent/US20220380285A1

## CPC

- A61P 17/00: Drugs for dermatological disorders
- C07C 43/253: containing hydroxy or O-metal groups
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07C 37/055: the substituted group being bound to oxygen, e.g. ether group
- C07C 39/21: with at least one hydroxy group on a non-condensed ring
- C07C 39/215: containing [IMAGE cpc-sch-C07C-0957.gif], e.g. diethylstilbestrol
- C07C 41/01: Preparation of ethers
- C07C 43/23: containing hydroxy or O-metal groups
- C07C 67/293: by isomerisation; by change of size of the carbon skeleton
- C07C 67/297: by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include or pharmaceutically acceptable salts or solvates thereof. R1a-R1d, R2-R3 (and R4 where applicable), and A---B can be as defined herein.

## Claims

### Claim 1

A compound according to structure USYDS1:
wherein the compound is in purified form.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the unpurified form of the compound originates from propolis, resin, gum, or exudate of the genus Lepidosperma.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the compound is chemically synthesised.

### Claim 4

A pharmaceutical composition comprising the compound according to structure USYDS1 and a pharmaceutical acceptable excipient:

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the compound is in purified form.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the composition is a sterile parenteral formulation.

### Claim 7 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the composition is an oral formulation.

### Claim 8 (depends on 5)

The pharmaceutical composition according to claim 5, wherein the composition is a topical formulation.

### Claim 9 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition is a sterile parenteral formulation.

### Claim 10 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition is an oral formulation.

### Claim 11 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the composition is a topical formulation.

### Claim 12 (depends on 6)

A method for treating inflammation, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 6 to a patient in need thereof.

### Claim 13 (depends on 6)

A method for treating immunosuppression, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 6 to a patient in need thereof.

### Claim 14 (depends on 6)

A method for treating a bacterial or fungal infection, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 6 to a patient in need thereof.

### Claim 15 (depends on 6)

A method for treating skin aging, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 6 to a patient in need thereof.

### Claim 16 (depends on 6)

A method for treating cancer, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 6 to a patient in need thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the cancer is leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, or breast cancer.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the cancer is responsive to Sirtuin 1 (SIRT1) inhibition.

### Claim 19

A compound, wherein the compound is a pharmaceutically acceptable salt of the compound according to structure USYDS1:

### Claim 20 (depends on 19)

A pharmaceutical composition comprising a compound and a pharmaceutical acceptable excipient, wherein the compound is the compound of claim 19.

### Claim 21 (depends on 1)

A method for preparing the compound according to claim 1, comprising:
providing a first compound of the following structure, where PG is a protecting group:
reacting this first compound to effect a rearrangement to prepare a second compound of the following structure:
deprotecting this second compound to prepare the compound according to structure USYDS1; and
purifying the compound according to structure USYDS1 to prepare the compound according to claim 1.

### Claim 22 (depends on 21)

The method of claim 21, comprising heating the first compound to effect the rearrangement to the second compound.
